N-benzylimidazo[1,2-a]pyridine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N-benzylimidazo[1,2-a]pyridine-2-carboxamide
• 化学式: C₁₅H₁₃N₃O
• mdl: MFCD17552396
• 分子量: 251.28
• InChiKey: BTTIGJALQUDFBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.066
• 拓扑面积：
  46.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• IDO-TDO dual inhibitor and related methods of use
  申请人：CMG PHARMACEUTICAL CO., LTD.

  公开号：US11370758B2

  公开（公告）日：2022-06-28

  Provided is an inhibitor of an indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) of formula (I) or a pharmaceutically acceptable salt thereof: in which W1, W2, W3, and W4, X, Y, Z1, Z2, and R1-7 are described herein. Further provided is a method of treating or preventing a IDO and/or TDO-mediated disease using an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

  本发明提供了一种式（I）的吲哚胺 2，3-二氧化酶（IDO）和/或色氨酸 2，3-二氧化酶（TDO）抑制剂或其药学上可接受的盐： 其中 W1、W2、W3 和 W4、X、Y、Z1、Z2 和 R1-7 已在本文中描述。进一步提供了一种使用有效量的式（I）化合物或其药学上可接受的盐治疗或预防 IDO 和/或 TDO 介导的疾病的方法。
• IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE
  申请人：CMG PHARMACEUTICAL CO., LTD.

  公开号：US20190292150A1

  公开（公告）日：2019-09-26

  Provided is an inhibitor of an indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) of formula (I) or a pharmaceutically acceptable salt thereof: in which W 1 , W 2 , W 3 , and W 4 , X, Y, Z 1 , Z 2 , and R 1-7 are described herein. Further provided is a method of treating or preventing a IDO and/or TDO-mediated disease using an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
• [EN] IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE<br/>[FR] INHIBITEUR DOUBLE DE IDO-TDO ET PROCÉDÉ D'UTILISATION ASSOCIÉS
  申请人：CMG PHARMACEUTICAL CO LTD

  公开号：WO2019180686A1

  公开（公告）日：2019-09-26

  Provided is an inhibitor of an indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) of formula (I) or a pharmaceutically acceptable salt thereof, in which W1, W2, W3, and W4, X, Y, Z1, Z2, and R1-7 are described herein. Further provided is a method of treating or preventing a IDO and/or TDO-mediated disease using an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.